Primary and key secondary endpoints
SECONDARY
The primary endpoint of the study was the proportion of participants with a ≥15-letter improvement (amended from ≥10-letter improvement, in accordance with US regulatory requirements) from baseline in BCVA at 12 months as measured by the ETDRS chart. The key secondary endpoints were the mean change from baseline in BCVA at 12 months measured by the ETDRS chart, the proportion of participants with a ≥10-letter ETDRS improvement from baseline in BCVA and the proportion of participants with no decrease in BCVA from baseline or a decrease of <5 ETDRS letters from baseline at 12 months.